{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04387942",
      "orgStudyIdInfo": {
        "id": "20K012-001"
      },
      "organization": {
        "fullName": "The First Hospital of Jilin University",
        "class": "OTHER"
      },
      "briefTitle": "The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura",
      "officialTitle": "The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura",
      "acronym": "HSP"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-06-14",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-05-31",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-06-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-05-06",
      "studyFirstSubmitQcDate": "2020-05-10",
      "studyFirstPostDateStruct": {
        "date": "2020-05-14",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-08-16",
      "lastUpdatePostDateStruct": {
        "date": "2022-08-18",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "The First Hospital of Jilin University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.",
      "detailedDescription": "The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore its efficacy and to observe changes in immune cell subsets and cytokines.For all patients,rhIL-2(500,000 unit per square meter) infusions seven days;recurrent patients were applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months."
    },
    "conditionsModule": {
      "conditions": [
        "Purpura, Schoenlein-Henoch"
      ],
      "keywords": [
        "HSP"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "CROSSOVER",
        "interventionModelDescription": "group A:patients were treated with IL-2.group B:patients were not treated with IL-2.",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 59,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Recombinant Human Interleukin-2",
          "type": "EXPERIMENTAL",
          "description": "patients were treated with IL-2.",
          "interventionNames": [
            "Drug: IL-2"
          ]
        },
        {
          "label": "Traditional therapy",
          "type": "NO_INTERVENTION",
          "description": "patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor."
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "IL-2",
          "description": "For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.",
          "armGroupLabels": [
            "Recombinant Human Interleukin-2"
          ],
          "otherNames": [
            "Recombinant Human Interleukin-2 for Injection"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "The change of immunological responses",
          "description": "Enumeration of the number of subjects with a change in the absolute number of immune cells and serum cytokines in the peripheral blood",
          "timeFrame": "day 0,day 7"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "The value of serum immunoglobulins and complements",
          "description": "Laboratory measures were detected, including,serum total IgE, serum Ig A,serum IgG,serum IgM,C3 and C4.",
          "timeFrame": "day 0,day 7,3 month,6 month"
        },
        {
          "measure": "Incidence of adverse drug reactions",
          "description": "Adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event,drug-induced liver and kidney damage.",
          "timeFrame": "up to 6 month"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. age \\<18 years old\n2. meet the EULAR/PRINTO/PRES for the diagnosis of HSP\n3. HIV negative;Negative for HBV and HCV.\n\nExclusion Criteria:\n\n1. heart failure (cardiac function ≥ grade III NYHA)\n2. liver insufficiency (upper limit of normal range of transaminase \\> 2 times)\n3. renal insufficiency (creatinine clearance ≤30ml/min)\n4. acute or severe infections such as bacteremia and sepsis\n5. malignant tumor\n6. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month\n7. mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information\n8. Intestinal ischemia or perforated gastrointestinal bleeding requires surgery\n9. Inability to comply with IL-2 treatment regimen.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "maximumAge": "17 Years",
      "stdAges": [
        "CHILD"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Yang si rui, MD and PhD",
          "affiliation": "The First Hospital of Jilin University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Sirui Yang",
          "city": "Changchun",
          "state": "Changchun/JiLin",
          "zip": "130021",
          "country": "China",
          "geoPoint": {
            "lat": 43.88,
            "lon": 125.32278
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "29241772",
          "type": "BACKGROUND",
          "citation": "St John J, Vedak P, Garza-Mayers AC, Hoang MP, Nigwekar SU, Kroshinsky D. Location of skin lesions in Henoch-Schonlein purpura and its association with significant renal involvement. J Am Acad Dermatol. 2018 Jan;78(1):115-120. doi: 10.1016/j.jaad.2017.04.1122."
        },
        {
          "pmid": "21929599",
          "type": "BACKGROUND",
          "citation": "Jen HY, Chuang YH, Lin SC, Chiang BL, Yang YH. Increased serum interleukin-17 and peripheral Th17 cells in children with acute Henoch-Schonlein purpura. Pediatr Allergy Immunol. 2011 Dec;22(8):862-8. doi: 10.1111/j.1399-3038.2011.01198.x. Epub 2011 Sep 19."
        },
        {
          "pmid": "16227984",
          "type": "BACKGROUND",
          "citation": "Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142-51. doi: 10.1038/ni1263. Epub 2005 Oct 16."
        },
        {
          "pmid": "29677473",
          "type": "BACKGROUND",
          "citation": "Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol. 2018 Apr 26;36:411-433. doi: 10.1146/annurev-immunol-042617-053352."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D011695",
          "term": "IgA Vasculitis"
        }
      ],
      "ancestors": [
        {
          "id": "D014657",
          "term": "Vasculitis"
        },
        {
          "id": "D014652",
          "term": "Vascular Diseases"
        },
        {
          "id": "D002318",
          "term": "Cardiovascular Diseases"
        },
        {
          "id": "D011693",
          "term": "Purpura"
        },
        {
          "id": "D001778",
          "term": "Blood Coagulation Disorders"
        },
        {
          "id": "D006402",
          "term": "Hematologic Diseases"
        },
        {
          "id": "D006425",
          "term": "Hemic and Lymphatic Diseases"
        },
        {
          "id": "D020141",
          "term": "Hemostatic Disorders"
        },
        {
          "id": "D006474",
          "term": "Hemorrhagic Disorders"
        },
        {
          "id": "D017445",
          "term": "Skin Diseases, Vascular"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D007105",
          "term": "Immune Complex Diseases"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D006470",
          "term": "Hemorrhage"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        },
        {
          "id": "D012877",
          "term": "Skin Manifestations"
        },
        {
          "id": "D012816",
          "term": "Signs and Symptoms"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D007376",
          "term": "Interleukin-2"
        },
        {
          "id": "C082598",
          "term": "aldesleukin"
        },
        {
          "id": "D007267",
          "term": "Injections"
        }
      ],
      "ancestors": [
        {
          "id": "D007378",
          "term": "Interleukins"
        },
        {
          "id": "D016207",
          "term": "Cytokines"
        },
        {
          "id": "D036341",
          "term": "Intercellular Signaling Peptides and Proteins"
        },
        {
          "id": "D010455",
          "term": "Peptides"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D008222",
          "term": "Lymphokines"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D001685",
          "term": "Biological Factors"
        },
        {
          "id": "D004333",
          "term": "Drug Administration Routes"
        },
        {
          "id": "D004358",
          "term": "Drug Therapy"
        },
        {
          "id": "D013812",
          "term": "Therapeutics"
        }
      ]
    }
  },
  "hasResults": false
}